US Patent No: 4,259,314

Number of patents in Portfolio can not be more than 2000

Method and composition for the preparation of controlled long-acting pharmaceuticals

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method and composition for the preparation of controlled long-acting pharmaceuticals using a dry carrier or base material comprising an effective amount of hydroxypropyl methylcellulose and hydroxypropyl cellulose suitable for use with both hygroscopic and non-hygroscopic materials. The controlled long-acting products of the invention are suitable for use in the form of lozenges, buccal tablets, oral tablets or suppositories.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

  • Assignment data not available. Check USPTO

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Lowey, Hans 1045 Nine Acres La., Mamaroneck, NY 10541 4 189

Cited Art Landscape

  • No Cited Art to Display

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
EURO-CELTIQUE S.A. (8)
4,366,310 Controlled release compositions 45 1980
5,891,471 Pharmaceutical multiparticulates 84 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 93 1996
5,843,480 Controlled release diamorphine formulation 65 1996
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 60 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 93 1997
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 67 1999
8,557,286 Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix 0 2000
 
PENWEST PHARMACEUTICALS CO. (7)
4,994,276 Directly compressible sustained release excipient 70 1988
5,128,143 Sustained release excipient and tablet formulation 64 1990
5,135,757 Compressible sustained release solid dosage forms 46 1991
5,169,639 Controlled release verapamil tablets 34 1991
5,472,711 Agglomerated hydrophilic complexes with multi-phasic release characteristics 36 1992
5,478,574 Agglomerated hydrophilic complexes with multi-phasic release characteristics 28 1993
5,670,168 Agglomerated hydrophilic complexes with multi-phasic release characteristics 25 1996
 
PURDUE PHARMA L.P. (7)
5,965,161 Extruded multi-particulates 99 1994
5,958,452 Extruded orally administrable opioid formulations 123 1997
6,335,033 Melt-extrusion multiparticulates 64 1999
6,261,599 Melt-extruded orally administrable opioid formulations 103 1999
6,743,442 Melt-extruded orally administrable opioid formulations 33 2001
6,706,281 Melt-extrusion multiparticulates 35 2002
7,510,727 Melt-extrusion multiparticulates 1 2003
 
FOREST LABORATORIES, INC. (6)
4,369,172 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose 224 1981
4,389,393 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose 238 1982
4,795,327 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 37 1984
4,540,566 Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose 71 1984
4,849,229 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 30 1988
4,983,398 Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates 25 1988
 
RECKITT BENCKISER LLC (6)
6,372,252 Guaifenesin sustained release formulation and tablets 11 2000
6,955,821 Sustained release formulations of guaifenesin and additional drug ingredients 5 2002
7,985,420 Sustained release of guaifenesin combination drugs 0 2003
7,838,032 Sustained release of guaifenesin 0 2003
8,012,504 Sustained release of guaifenesin combination drugs 1 2003
7,985,421 Sustained release formulations of guaifenesin and additional drug ingredients 0 2005
 
ALZA CORPORATION (5)
4,786,503 Dosage form comprising parallel lamine 33 1987
4,851,232 Drug delivery system with means for obtaining desirable in vivo release rate pattern 47 1987
4,946,685 Cellulosic dosage form 58 1988
5,204,116 Dosage form providing immediate therapy followed by prolonged therapy 20 1991
5,338,550 Stereoisomer therapy 7 1992
 
Supernus Pharmaceuticals, Inc. (5)
8,709,476 Compositions of quaternary ammonium compounds containing bioavailability enhancers 0 2004
7,781,448 Once daily dosage forms of trospium 0 2007
7,781,449 Trospium chloride treatment method 0 2007
7,763,635 Once daily dosage forms of trospium 3 2007
7,759,359 Method of treating bladder dysfunction with once-a-day trospium salt formulation 0 2007
 
E. R. Squibb & Sons, Inc. (4)
4,505,890 Controlled release formulation and method 23 1983
4,610,870 Controlled release formulation 80 1984
4,666,705 Controlled release formulation 48 1985
4,756,911 Controlled release formulation 87 1986
 
NAPP PHARMACEUTICAL GROUP LIMITED (4)
5,591,452 Controlled release formulation 77 1994
6,326,027 Controlled release formulation 66 1995
6,254,887 Controlled release tramadol 62 1996
7,074,430 Controlled release tramadol tramadol formulation 18 2001
 
ABBOTT RESPIRATORY LLC (3)
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia 6 1997
6,746,691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics 6 1997
6,676,967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia 6 1997
 
CONCORDIA PHARMACEUTICALS, INC. (3)
5,484,607 Extended release clonidine formulation 16 1993
5,869,100 Extended release clonidine formulation (tablet) 10 1997
6,030,642 Extended release clonidine formulation (capsule) 10 1997
 
Key Pharmaceuticals, Inc. (3)
4,508,702 Sustained release aspirin 11 1984
4,555,399 Aspirin tablet 38 1984
4,634,587 Sustained release quinidine dosage form 21 1984
 
NOVARTIS AG (3)
6,242,003 Organic compounds 4 2000
6,432,447 Organic compounds 1 2001
8,303,987 Pharmaceutical compositions comprising fluvastatin 0 2010
 
SCHERING CORPORATION (3)
4,601,894 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate 24 1985
4,695,591 Controlled release dosage forms comprising hydroxypropylmethylcellulose 45 1985
4,657,757 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate 14 1985
 
The Dow Chemical Company (3)
4,695,464 Sustained release dosage form based on highly plasticized cellulose ether gels 28 1984
4,678,516 Sustained release dosage form based on highly plasticized cellulose ether gels 60 1984
4,734,285 Sustained release compositions 36 1985
 
CHRISTIAN HANSEN A/S (2)
5,645,830 Lactobacillus and skim milk compositions and methods for preventing microbial urogenital infections 14 1994
6,004,551 Lactobacillus and skim milk pharmaceutical compositions 10 1996
 
HERCULES INCORPORATED (2)
5,480,984 Process of preparing high solids low viscosity polysaccharides 6 1992
6,210,710 Sustained release polymer blend for pharmaceutical applications 37 1997
 
KOS LIFE SCIENCES LLC (2)
6,080,428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 4 1995
6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night 8 1997
 
Mead Johnson & Company (2)
4,465,660 Sustained release tablet containing at least 95 percent theophylline 23 1982
4,547,358 Sustained release tablet containing at least 95 percent theophylline 9 1984
 
TCF BANK SAVINGS FSB N/K/A TCF NATIONAL BANK (2)
5,126,145 Controlled release tablet containing water soluble medicament 105 1990
5,268,181 Method of using niacin to control nocturnal cholesterol synthesis 19 1992
 
Unitel Technologies, Inc. (2)
6,821,532 Methods and compositions for the treatment of benign prostatic hypertrophy 2 2001
6,733,796 Methods and compositions for the treatment of benign prostatic hypertrophy 3 2002
 
Aktiebolaget Hassle (1)
4,942,040 Pharmaceutical preparation and a process for its preparation 38 1988
 
ASTELLAS PHARMA INC. (1)
4,916,138 Solid dispersion composition of FR-900506 substance 56 1988
 
DRUGTECH CORPORATION (1)
5,445,829 Extended release pharmaceutical formulations 145 1992
 
EFFCON LABORATORIES, INC. (1)
6,214,381 Methazolamide composition and method of use 0 1998
 
ELAN CORPORATION, PLC (1)
6,110,494 Cisapride mini-tablet formulations 6 1997
 
FARVALSA A.G. (1)
4,837,032 Theophylline sustained release tablet 18 1986
 
FUJISAWA PHARMACEUTICAL CO., LTD. (1)
4,654,206 Fast release solid preparation of dihydropyridine a compound 14 1984
 
HOFFMANN-LA ROCHE INC. (1)
5,393,765 Pharmaceutical compositions with constant erosion volume for zero order controlled release 34 1993
 
KOS LIFE SCIENCES, INC. (1)
7,998,506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 0 2003
 
LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D. (1)
6,042,847 Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application 33 1997
 
NIPPON SODA CO., LTD. (1)
8,617,596 Sustained-release tablet production process 0 2007
 
NOSTRUM PHARMACEUTICALS, INC. (1)
7,179,486 Process for preparing sustained release tablets 6 2001
 
PALMETTO PHARMACEUTICALS, LLC (1)
7,381,731 Pharmaceutical composition comprising citrulline 0 2004
 
Plastic Dress-Up Co. (1)
5,895,663 Pseudoephedrine hydrochloride extended-release tablets 15 1997
 
RANBAXY LABORATORIES LIMITED (1)
6,960,356 Orally administered drug delivery system providing temporal and spatial control 9 1999
 
RANBAXY RESEARCH LABORATORIES (1)
5,948,440 Modified release matrix formulation of cefaclor and cephalexin 12 1997
 
Sandoz Ltd. (1)
5,069,911 Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions 3 1990
 
SHIN-ETSU CHEMICAL CO., LTD. (1)
5,476,668 Base for film-coating pharmaceuticals and method for preparing same 4 1993
 
SHIONOGI INC. (1)
7,884,122 Extended release formulation and method of treating adrenergic dysregulation 1 2009
 
Societe Civile dite: "Medibrevex" (1)
5,061,493 Galenical forms of corticoids for administration perlingually and sublingually and process for their preparation 2 1988
 
SYNGENTA LIMITED (1)
5,948,437 Pharmaceutical compositions using thiazepine 20 1997
 
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6,337,091 Matrix for controlled delivery of highly soluble pharmaceutical agents 15 1997
 
VALEANT INTERNATIONAL BERMUDA (1)
6,893,661 Controlled release formulations using intelligent polymers 9 1998
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
5,840,756 Pharmaceutical composition of L-DOPA ester 24 1996
 
Other [Check patent profile for assignment information] (4)
4,680,323 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration 36 1983
4,775,535 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1986
4,855,143 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 21 1988
6,264,974 Buccal and sublingual administration of physostigmine 5 1998